Onyx-Bayer colorectal cancer drug Stivarga gains FDA approval

09/27/2012 | CNBC

The FDA approved Onyx Pharmaceuticals and Bayer HealthCare's Stivarga, or regorafenib, to treat patients whose colorectal cancer has metastasized and progressed after therapy. The drug, also being reviewed for gastrointestinal stromal tumors, will be marketed jointly.

View Full Article in:

CNBC

Published in Briefs: